At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise

12:26 EDT 17 Apr 2018 | SCRIP

Global oncology sales grew 45% to $2.31bn in the first quarter, powered by strong growth of Darzalex, Imbruvica and Zytiga...

More From BioPortfolio on "At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise"